Evidence map›Paper›PMID 36809489›Full record

SynthesisNeuro-oncology2023

Cognitive outcomes after multimodal treatment in adult glioma patients: A meta-analysis.

Laurien De Roeck, Céline R Gillebert, Robbie C M van Aert, Amber Vanmeenen, Martin Klein, Martin J B Taphoorn, Karin Gehring, Maarten Lambrecht, Charlotte Sleurs

Open access · hybridAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Laurien De RoeckDepartment of Oncology, KU Leuven, Leuven, Belgium.ORCID 0000-0002-2571-1816
Céline R GillebertDepartment of Brain and Cognition, Leuven Brain Institute (LBI), KU Leuven, Leuven, Belgium.ORCID 0000-0001-6686-7262
Robbie C M van AertDepartment of Methodology and Statistics, Tilburg University, Tilburg, The Netherlands.ORCID 0000-0001-6187-0665
Amber VanmeenenDepartment of Brain and Cognition, Leuven Brain Institute (LBI), KU Leuven, Leuven, Belgium.
Martin KleinDepartment of Medical Psychology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0001-5553-7911
Martin J B TaphoornDepartment of Neurology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0001-9949-4722
Karin GehringDepartment of Cognitive Neuropsychology, Tilburg University, Tilburg, The Netherlands.
Maarten LambrechtDepartment of Brain and Cognition, Leuven Brain Institute (LBI), KU Leuven, Leuven, Belgium.ORCID 0000-0002-8746-2691
Charlotte SleursDepartment of Brain and Cognition, Leuven Brain Institute (LBI), KU Leuven, Leuven, Belgium.ORCID 0000-0002-4480-8330
VIB-KU Leuven Center for Brain & Disease Research · BETilburg University · NLAmsterdam University Medical Centers · NLElisabeth-TweeSteden Ziekenhuis · NLLeiden University Medical Center · NLZiekenhuis Oost-Limburg · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCognitive functioning is increasingly assessed as a secondary outcome in neuro-oncological trials. However, which cognitive domains or tests to assess, remains debatable. In this meta-analysis, we aimed to elucidate the longer-term test-specific cognitive outcomes in adult glioma patients.

methodsA systematic search yielded 7098 articles for screening. To investigate cognitive changes in glioma patients and differences between patients and controls 1-year follow-up, random-effects meta-analyses were conducted per cognitive test, separately for studies with a longitudinal and cross-sectional design. A meta-regression analysis with a moderator for interval testing (additional cognitive testing between baseline and 1-year posttreatment) was performed to investigate the impact of practice in longitudinal designs.

resultsEighty-three studies were reviewed, of which 37 were analyzed in the meta-analysis, involving 4078 patients. In longitudinal designs, semantic fluency was the most sensitive test to detect cognitive decline over time. Cognitive performance on mini-mental state exam (MMSE), digit span forward, phonemic and semantic fluency declined over time in patients who had no interval testing. In cross-sectional studies, patients performed worse than controls on the MMSE, digit span backward, semantic fluency, Stroop speed interference task, trail-making test B, and finger tapping.

conclusionsCognitive performance of glioma patients 1 year after treatment is significantly lower compared to the norm, with specific tests potentially being more sensitive. Cognitive decline over time occurs as well, but can easily be overlooked in longitudinal designs due to practice effects (as a result of interval testing). It is warranted to sufficiently correct for practice effects in future longitudinal trials.

Indexed as

Cognition DisordersGliomaAdultCognitionCombined Modality TherapyCross-Sectional StudiesHumansNeuropsychological TestsAdultCognitionCognitive evaluationGliomaMeta-analysis

Identifiers

PMID36809489
PMCPMC10398801
OpenAlexW4321435778

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.